UV-Cap GmbH & Co KG, Ravensburg, has acquired Scil Proteins – the protein engineering company for affinity ligands and targeted carriers – from Bionet Ventures GmbH, Munich.
The new Navigo Proteins will operate through two separate business units: Navigo Precision Targeting and Navigo Precision Capturing. All staff and management will be retained.
Navigo Precision Targeting will focus on diagnostics, imaging and therapeutics, while Navigo Precision Capturing will produce affinity products for biopharmaceutical manufacturing.
This structure will support continued growth and accelerate Navigo Proteins’ commercialisation strategy.
Udo J. Vetter, Founder and Managing Director of UV-Cap said: “We are excited to be able to support the long term aspiration of the team at the new Navigo Proteins.”
“The technologies hold great potential to help to expand therapeutic pipelines and accelerate product development.”
Brian Hunter, Managing Director of BioNet Ventures said: “We are pleased that the management and team will continue to focus on collaborations with industrial partners from the bioprocessing, targeted imaging and therapy and precision diagnostics industries.”
Henning Afflerbach, CEO of Navigo Proteins said: “UV-Cap’s global industry network and in-depth knowledge of the biopharmaceutical sector will further support our mission to provide novel targeted molecules for use in both precision medicine and biomanufacturing.”